75665-88-2

Basic information

• Product Name: Ethanone, 1-[5-Methoxy-2-nitro-4-(phenylMethoxy)phenyl]-
• Synonyms: Ethanone, 1-[5-Methoxy-2-nitro-4-(phenylMethoxy)phenyl]-;6-Nitro-O-benzylacetovanillone;1-(4-Benzyloxy-5-methoxy-2-nitro-phenyl)-ethanone
• CAS NO: 75665-88-2
• Molecular Formula: C₁₆H₁₅NO₅
• Molecular Weight: 301.294
• Mol File: 75665-88-2.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 488.1±40.0 °C(Predicted)
• Appearance: /
• Density: 1.247±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Ethanone, 1-[5-Methoxy-2-nitro-4-(phenylMethoxy)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 1-[5-Methoxy-2-nitro-4-(phenylMethoxy)phenyl]-(75665-88-2)
• EPA Substance Registry System: Ethanone, 1-[5-Methoxy-2-nitro-4-(phenylMethoxy)phenyl]-(75665-88-2)

Safety Data

• Hazardous Substances Data: 75665-88-2(Hazardous Substances Data)

Usage

Description

Ethanone, 1-[5-methoxy-2-nitro-4-(phenylmethoxy)phenyl]-, also known as 5-MeO-DiPT, is a synthetic chemical compound belonging to the tryptamine class. It is a psychedelic hallucinogen structurally related to dimethyltryptamine, known for inducing profound sensory distortions, intense visual and auditory hallucinations, and altered states of consciousness. As a psychoactive substance, 5-MeO-DiPT may have the potential for misuse and abuse, and its effects on human health and long-term consequences are not fully understood. It has been listed as a controlled substance in some countries, with regulated sale and possession.

Uses

Used in Research Applications:
5-MeO-DiPT is utilized as a research chemical for studying the effects of psychedelic substances on the human brain and their potential therapeutic applications. Its psychoactive properties allow researchers to explore the underlying mechanisms of hallucinations, altered states of consciousness, and the neural correlates of these experiences.
Used in Pharmaceutical Development:
Although its long-term health consequences are not fully understood, 5-MeO-DiPT may be used in the development of new pharmaceuticals targeting mental health disorders. Its structural similarity to dimethyltryptamine and other tryptamine-based compounds could provide insights into the development of novel treatments for conditions such as depression, anxiety, and post-traumatic stress disorder (PTSD).
Used in Forensic Toxicology:
5-MeO-DiPT, being a controlled substance, is also used in forensic toxicology for the identification and analysis of its presence in biological samples. This helps in the investigation of drug-related crimes and the assessment of substance abuse patterns.
Used in Drug Policy and Regulation:
The classification of 5-MeO-DiPT as a controlled substance in some countries contributes to the development and enforcement of drug policies and regulations. Its inclusion in these policies aids in the prevention of misuse and abuse, ensuring public health and safety.

Upstream product

• 100-39-0 benzyl bromide 
• 498-02-2 1-(3-methoxy-4-hydroxyphenyl)ethanone 
• 1835-11-6 4-benzyloxy-3-methoxyacetophenone 

Downstream Products

• 1260586-85-3 2-methyl-2-(5-methoxy-2-nitro-4-propargyloxyphenyl)-1,3-dioxolane 
• 1260586-86-4 2-(5-methoxy-2-nitro-4-propargyloxy-α-methylbenzyloxy)ethanol 
• 1260586-89-7 C₆₅H₉₄N₂O₁₈ 
• 221112-24-9 4-(3-hydroxypropoxy)-3-methoxy-6-nitroacetophenone 
• 516526-32-2 4-(7-benzyloxy-6-methoxyquinolin-4-yloxy)aniline 

Relevant articles and documents

Heterocyclic compound, preparation method and application thereof

The invention relates to a heterocyclic compound in the technical field of medicines. The compound is represented by a structural general formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, X, Y, Z, Cy1, Cy2, m, n and t have the meanings given in the specification; in addition, the invention also discloses an application of the compound and the pharmaceuticallyacceptable salt thereof in preparation of drugs for treating diseases caused by abnormal high expression of tyrosine kinase, especially application in preparation of drugs for treating and preventingcancers.

CARBAMATE AND UREA COMPOUNDS AS MULTIKINASE INHIBITORS

The present disclosure describes carbamate and urea compounds as novel multikinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such multikinase inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders associated with kinases are also described.

Quinoline or quinazoline derivatives as well as preparation method and application thereof

The invention relates to quinoline or quinazoline derivatives as well as a preparation method and an application thereof, namely, the quinoline or quinazoline derivatives shown as the formula I as well as pharmaceutically acceptable salts and hydrates or prodrugs of the quinoline or quinazoline derivatives. The structure is shown in the specification, wherein A1, A2, R1, R2, R3, R4, R5, R6, X, Y, Z, M, W, Cy1, Cy2, m and n are defined in the specification. The invention further relates to the function of the compounds in the general formula I for inhibiting MET kinase and the application of the compounds as well as the pharmaceutically acceptable salts and hydrates of the compounds in preparation of drugs for treating diseases caused by abnormal high expression of the MET kinase, in particular to the application in preparation of drugs for treating and preventing cancer.